» Articles » PMID: 23340708

Clinicopathological Features of Recurrence in Patients After 10-year Disease-free Survival Following Curative Hepatic Resection of Hepatocellular Carcinoma

Abstract

Background: The present study aimed to clarify the clinicopathologic features of long-term disease-fee survival after resection of hepatocellular carcinoma (HCC).

Methods: This retrospective study identified 940 patients who underwent curative resection of HCC between 1991 and 2000 at five university hospitals. Seventy-four patients with 10 years of recurrence-free survival were identified and followed up. They were divided into two groups, 60 recurrence-free and 14 with recurrence after a 10-year recurrence-free period.

Results: Overall survival rates of recurrence and non-recurrence groups were 68 and 91 % at 16 years, and 34 and 91 % at 20 years (p = 0.02), respectively. There were five (36 %), and two deaths (3 %), respectively, after 10 recurrence-free years. A second resection for recurrence was performed in four patients (29 %), and mean survival was 15.3 years after the first hepatectomy. Although three patients in the non-recurrence group (5 %) developed esophageal and/or gastric varices, seven patients in the recurrence group (50 %) developed varices during 10 years (p < 0.0001). In multivariate analysis, preoperative and 10-year platelet count was identified as a favorable independent factor for maintained recurrence-free survival after a 10-year recurrence-free period following curative hepatic resection of HCC.

Conclusions: Recurrence of HCC may occur even after a 10-year recurrence-free period. Long-term follow-up after resection of HCC is important, and should be life-long. Patients with higher preoperative and 10-year platelet counts are more likely to have long-term survival after resection. A low platelet count, related to the degree of liver fibrosis, is a risk factor for recurrence and survival of HCC after curative resection.

Citing Articles

Survival analysis of patients with hepatocellular carcinoma based on the ratio of platelet count to spleen diameter.

Yan H, Zhou D, Liu X, Wang P, Jiang T, Yang Z Front Pharmacol. 2025; 15():1449603.

PMID: 39834808 PMC: 11744000. DOI: 10.3389/fphar.2024.1449603.


FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: A meta-analysis.

Zhang Y, Wang R, Yang X Medicine (Baltimore). 2018; 97(51):e13696.

PMID: 30572498 PMC: 6320186. DOI: 10.1097/MD.0000000000013696.


Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status.

Koda M, Tanaka S, Takemura S, Shinkawa H, Kinoshita M, Hamano G Liver Cancer. 2018; 7(3):261-276.

PMID: 30319984 PMC: 6170901. DOI: 10.1159/000486902.


Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma.

Ho S, Liu P, Hsu C, Hsia C, Su C, He Y Sci Rep. 2018; 8(1):15074.

PMID: 30305679 PMC: 6180073. DOI: 10.1038/s41598-018-33536-2.


Differences in the impact of prognostic factors for hepatocellular carcinoma over time.

Toyoda H, Kumada T, Tada T, Yama T, Mizuno K, Sone Y Cancer Sci. 2017; 108(12):2438-2444.

PMID: 28945309 PMC: 5715354. DOI: 10.1111/cas.13406.


References
1.
Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M . Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet. 1998; 351(9118):1773-7. DOI: 10.1016/S0140-6736(97)08002-1. View

2.
Lee P, Lin W, Tsang Y, Hu R, Sheu J, Lai M . Clinical management of recurrent hepatocellular carcinoma. Ann Surg. 1995; 222(5):670-6. PMC: 1234995. DOI: 10.1097/00000658-199511000-00010. View

3.
Kosuge T, Makuuchi M, Takayama T, Yamamoto J, Shimada K, Yamasaki S . Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology. 1993; 40(4):328-32. View

4.
Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Ito Y . Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer. 1994; 73(4):1149-54. DOI: 10.1002/1097-0142(19940215)73:4<1149::aid-cncr2820730405>3.0.co;2-9. View

5.
Schmidt K, Rasmussen J, Bekker C, MADSEN P . Kinetics and in vivo distribution of 111-In-labelled autologous platelets in chronic hepatic disease: mechanisms of thrombocytopenia. Scand J Haematol. 1985; 34(1):39-46. DOI: 10.1111/j.1600-0609.1985.tb00742.x. View